• Featured Product
  • KD/KO Validated

CoraLite® Plus 488-conjugated PRAME Monoclonal antibody

PRAME Monoclonal Antibody for IF/ICC

Host / Isotype

Mouse / IgG2b

Reactivity

Human, mouse, rat

Applications

IF/ICC

Conjugate

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

1E9G9

Cat no : CL488-68097

Synonyms

MAPE, OIP 4, OIP4, Opa interacting protein 4, PRAME



Tested Applications

Positive IF/ICC detected inHaCaT cells

Recommended dilution

ApplicationDilution
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

CL488-68097 targets PRAME in IF/ICC applications and shows reactivity with Human, mouse, rat samples.

Tested Reactivity Human, mouse, rat
Host / Isotype Mouse / IgG2b
Class Monoclonal
Type Antibody
Immunogen PRAME fusion protein Ag1906
Full Name preferentially expressed antigen in melanoma
Calculated Molecular Weight 509 aa, 58 kDa
Observed Molecular Weight50 kDa
GenBank Accession NumberBC014074
Gene Symbol PRAME
Gene ID (NCBI) 23532
Conjugate CoraLite® Plus 488 Fluorescent Dye
Excitation/Emission Maxima Wavelengths493 nm / 522 nm
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
Storage ConditionsStore at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

The PRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. It is considered a melanocyte differentiation antigen which is overexpressed in both solid and hematologic tumors. In normal tissue, a very low level of PRAME expression is found in normal testis, adrenals, ovary and endometrium. A high level of PRAME expression has been reported for several solid tumors, including ovarian cancer, breast cancer, lung cancer and melanomas, medulloblastoma, sarcomas, head and neck cancers, neuroblastoma, renal cancer, and Wilms'tumor. As a nuclear transcriptional repressor protein, PRAME binds to retinoic acid receptor a, thereby inhibiting retinoic acid induced differentiation, growth arrest, and apoptosis.

Protocols

Product Specific Protocols
IF protocol for CL Plus 488 PRAME antibody CL488-68097Download protocol
Standard Protocols
Click here to view our Standard Protocols